(NASDAQ: ELEV) Elevation Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Elevation Oncology's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ELEV's revenue for 2027 to be $726,361,147, with the lowest ELEV revenue forecast at $32,109,736, and the highest ELEV revenue forecast at $1,420,612,558. On average, 2 Wall Street analysts forecast ELEV's revenue for 2028 to be $1,340,581,474, with the lowest ELEV revenue forecast at $216,010,951, and the highest ELEV revenue forecast at $2,465,151,997.
In 2029, ELEV is forecast to generate $7,509,542,856 in revenue, with the lowest revenue forecast at $5,380,813,319 and the highest revenue forecast at $9,638,272,393.